This agreement is in addition to the $92 million filling line expansion announced in November 2021
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
The life sciences and pharmaceutical sectors suffer from hard-to-source biological materials, which translates into high costs in research and development
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
The 50,000 square foot expansion will house a high-speed filling line and lyophilizers, which will increase the facility’s sterile injectable capacity by 50%
Subscribe To Our Newsletter & Stay Updated
